Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

141. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis

Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis 29377473 2018 03 08 1463-1326 2018 Jan 27 Diabetes, obesity & metabolism Diabetes Obes Metab Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. 10.1111/dom.13235 To investigate the effect (...) of two clinically applied proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9-mAbs) on glycaemia and new-onset diabetes mellitus (NODM). PubMed, MEDLINE, Embase, Cochrane databases and ClinicalTrials.gov websites were systematically searched for randomized controlled trials that reported data on fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) or NODM incidence. Risk ratios (RRs) for NODM and mean difference (MD) for FPG and HbA1c with 95% confidence intervals (CIs

EvidenceUpdates2018

142. Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes Mellitus

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes Mellitus 29472432 2018 02 23 1935-5548 2018 Feb 22 Diabetes care Diabetes Care Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes Mellitus. dc170968 10.2337/dc17-0968 In clinical trials, treatment with fenofibrate did not reduce the incidence of major cardiovascular events (MCVE) in patients with type 2 diabetes mellitus (T2DM). However (...) effect was larger in patients with dyslipidemia. The method of individualized treatment effect prediction of fenofibrate on MCVE risk reduction in T2DM can be used to guide clinical decision-making. © 2018 by the American Diabetes Association. Koopal Charlotte C Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands. Visseren Frank L J FLJ http://orcid.org/0000-0003-3951-5223 Department of Vascular Medicine, University Medical Center Utrecht, Utrecht

EvidenceUpdates2018

143. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study

Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study 29316176 2018 04 15 1463-1326 20 5 2018 May Diabetes, obesity & metabolism Diabetes Obes Metab Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study. 1186-1192 (...) 10.1111/dom.13214 To evaluate the glycaemic control achieved by prandial once-daily insulin glulisine injection timing adjustment, based on a continuous glucose monitoring sensor, in comparison to once-daily insulin glulisine injection before breakfast in patients with type 2 diabetes who are uncontrolled with once-daily basal insulin glargine. This was a 24-week open-label, randomized, controlled, multicentre trial. At the end of an 8-week period of basal insulin optimization, patients with HbA1c

EvidenceUpdates2018

144. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial

Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial 29535135 2018 03 14 1935-5548 2018 Mar 13 Diabetes care Diabetes Care Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. dc172534 10.2337/dc17-2534 Despite advances in technology, optimal glucose control remains elusive and neonatal complications ubiquitous (...) in type 1 diabetes (T1D) pregnancy. Our aim was to examine the safety, efficacy, and longer-term feasibility of day-and-night closed-loop insulin delivery. We recruited 16 pregnant women (mean [SD]: age 32.8 [5.0] years, T1D duration 19.4 [10.2] years, HbA 1c 8.0% [1.1%], BMI 26.6 [4.4] kg/m 2 ) to an open-label, randomized, crossover trial. Participants completed 28 days of closed-loop and sensor-augmented pump (SAP) insulin delivery separated by a washout period. Afterward, participants could

EvidenceUpdates2018

145. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians

) instrument was used to evaluate the guidelines. Guidance Statement 1: Clinicians should personalize goals for glycemic control in patients with type 2 diabetes on the basis of a discussion of benefits and harms of pharmacotherapy, patients' preferences, patients' general health and life expectancy, treatment burden, and costs of care. Guidance Statement 2: Clinicians should aim to achieve an HbA 1c level between 7% and 8% in most patients with type 2 diabetes. Guidance Statement 3: Clinicians should (...) and any hypoglycemia were more common in the intensive therapy group than the standard therapy group. This included a 3-fold higher rate of episodes with impaired consciousness (9 vs. 3 episodes per 100 patient-years). Serious adverse events were also more common in the intensive therapy group (24.1% vs. 17.6%; P = 0.05); dyspnea was the most common ( P = 0.006) ( ). Guidance Statements Guidance Statement 1: Clinicians should personalize goals for glycemic control in patients with type 2 diabetes on

American College of Physicians2018

147. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. OBJECTIVE: To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of inflammatory bowel disease in patients with type 2 diabetes. DESIGN: Population based cohort study. SETTING: More than 700 general practices contributing data to the United Kingdom Clinical Practice Research Datalink. PARTICIPANTS: A cohort (...) of 141 170 patients, at least 18 years of age, starting antidiabetic drugs between 1 January 2007 and 31 December 2016, with follow-up until 30 June 2017. MAIN OUTCOME MEASURES: Adjusted hazard ratios for incident inflammatory bowel disease associated with use of dipeptidyl peptidase-4 inhibitors overall, by cumulative duration of use, and by time since initiation, estimated using time dependent Cox proportional hazards models. Use of dipeptidyl peptidase-4 inhibitors was modelled as a time varying

BMJ2018

148. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.

Guidelines Network, and the U.S. Department of Veterans Affairs and Department of Defense. The AGREE II (Appraisal of Guidelines for Research and Evaluation II) instrument was used to evaluate the guidelines. Guidance Statement 1: Clinicians should personalize goals for glycemic control in patients with type 2 diabetes on the basis of a discussion of benefits and harms of pharmacotherapy, patients' preferences, patients' general health and life expectancy, treatment burden, and costs of care. Guidance (...) Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Description: The American College of Physicians developed this guidance statement to guide clinicians in selecting targets for pharmacologic treatment of type 2 diabetes. Methods: The National Guideline Clearinghouse and the Guidelines International Network library were searched (May 2017) for national

Annals of Internal Medicine2018

149. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India

Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India 1 Evans V, et al. BMJ Glob Health 2018;3:e000263. doi:10.1136/bmjgh-2016-000263 Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India Valerie Evans, 1,2 Peter Roderick, 3 Allyson M Pollock 3 Analysis To cite: Evans V, Roderick P , Pollock AM. Adequacy of clinical trial evidence of metformin fixed (...) -dose combinations for the treatment of type 2 diabetes mellitus in India. BMJ Glob Health 2018;3:e000263. doi:10.1136/ bmjgh-2016-000263 Handling editor Seye Abimbola Received 5 December 2016 Revised 15 September 2017 Accepted 21 September 2017 1 School of Social and Political Science, University of Edinburgh, Edinburgh, UK 2 Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, USA 3 Institute

BMJ global health2018 Full Text: Link to full Text with Trip Pro

150. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial 29483185 2018 02 27 1935-5548 2018 Feb 26 Diabetes care Diabetes Care Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial. dc171114 10.2337/dc17-1114 In patients with uncontrolled (...) type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart four or fewer times per day. Glycated hemoglobin (HbA 1c ) decreased from 8.2% (66 mmol/mol) to 6.7% (50 mmol/mol

EvidenceUpdates2018

151. Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks

Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks 29378776 2018 01 30 1935-5548 2018 Jan 29 Diabetes care Diabetes Care Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks. dc171618 10.2337/dc17-1618 The current study investigated whether the risk of mortality in patients with type 1 diabetes without any signs of albuminuria is different than (...) in the general population and matched control subjects without diabetes. We studied a nationwide, population-based Finnish register of 10,737 patients diagnosed with type 1 diabetes during 1980-2005 and followed for 10 years and 2,544 adults with long-standing diabetes drawn from the Finnish Diabetic Nephropathy Study (FinnDiane). Mortality was compared with the general Finnish population and 6,655 control subjects without diabetes. Standardized mortality ratio (SMR) was increased during the first 10 years

EvidenceUpdates2018

152. Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice

J Health Promot. 2006 Nov-Dec;21(2):85-9 17152246 JAMA. 2011 May 4;305(17):1790-9 21540423 Ann Afr Med. 2014 Oct-Dec;13(4):189-94 25287033 J Phys Act Health. 2010 Nov;7(6):737-45 21088304 Diabetes Care. 2010 Dec;33(12):e147-67 21115758 Nigeria blood glucose general practice physical activity type 2 diabetes mellitus walking 2017 06 04 2017 10 05 2019 02 01 2018 1 18 6 0 2018 1 18 6 0 2018 1 17 6 0 ppublish 29335328 bjgp18X694613 10.3399/bjgp18X694613 PMC5774965 (...) Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice 29335328 2018 02 01 1478-5242 68 667 2018 Feb The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice. e139-e145 10.3399/bjgp18X694613 In clinical practice, translating

EvidenceUpdates2018

153. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial

Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial 29285796 2018 02 13 1464-5491 35 3 2018 Mar Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial. 339-346 10.1111/dme.13576 To test whether weight-based treatment is more (...) effective than usual care in people with Type 1 diabetes receiving continuous subcutaneous insulin infusion therapy with regard to both hypoglycaemia and avoiding excessive rebound hyperglycaemia. Children and adults on continuous subcutaneous insulin infusion were enrolled into a study with a crossover design. Each episode of hypoglycaemia (defined as capillary glucose <4.0 mmol/l) was randomly assigned one of two treatment protocols using glucose tablets: either 0.3 g/kg body weight or usual treatment

EvidenceUpdates2018

154. Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes

Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes 29371234 2018 01 26 1935-5548 2018 Jan 25 Diabetes care Diabetes Care Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes. dc170090 10.2337/dc17-0090 This study examines whether participation in an 18-month (...) behavioral intervention shown previously to improve overall diet quality inadvertently increases disordered eating behaviors (DEBs) in youth with type 1 diabetes and investigates the association of DEB with multiple measures of glycemic control and variability. Participants reported DEB and diabetes management at baseline and 6, 12, and 18 months; masked continuous glucose monitoring (CGM), HbA 1c , and 1,5-anhydroglucitol were obtained concurrently. Linear mixed models estimated the intervention effect

EvidenceUpdates2018

155. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

-weekly subcutaneous semaglutide as monotherapy or combined with an oral antidiabetic drug (OAD) vs an additional OAD added to background therapy in Japanese people with type 2 diabetes (T2D) inadequately controlled on diet/exercise or OAD monotherapy. In this phase III, open-label trial, adults with T2D were randomized 2:2:1 to semaglutide 0.5 mg or 1.0 mg, or one additional OAD (a dipeptidyl peptidase-4 inhibitor, biguanide, sulphonylurea, glinide, α-glucosidase inhibitor or thiazolidinedione (...) , Japan. eng Journal Article 2018 01 11 England Diabetes Obes Metab 100883645 1462-8902 GLP-1 analogue glycaemic control incretin therapy phase III study randomized trial type 2 diabetes 2017 08 04 2017 12 29 2018 01 08 2018 1 13 6 0 2018 1 13 6 0 2018 1 12 6 0 aheadofprint 29322610 10.1111/dom.13218

EvidenceUpdates2018

156. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis

-0002-0980-8896 Department of Pharmacy, Peking University Third Hospital, Beijing, China. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. eng Journal Article 2018 01 25 England Diabetes Obes Metab 100883645 1462-8902 antidiabetic drug diabetic retinopathy network meta-analysis type 2 diabetes 2017 11 13 2018 01 11 2018 01 19 2018 1 26 6 0 2018 1 26 6 0 2018 1 26 6 0 aheadofprint 29369494 10.1111/dom.13232 (...) Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis 29369494 2018 02 23 1463-1326 2018 Jan 25 Diabetes, obesity & metabolism Diabetes Obes Metab Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. 10.1111/dom.13232 To assess the comparative effects of glucose-lowering drugs (GLDs) on the risk

EvidenceUpdates2018

157. The role of telenursing in the management of Diabetes Type 1: A randomized controlled trial

The role of telenursing in the management of Diabetes Type 1: A randomized controlled trial 29353709 2018 03 17 1873-491X 80 2018 Jan 06 International journal of nursing studies Int J Nurs Stud The role of telenursing in the management of Diabetes Type 1: A randomized controlled trial. 29-35 S0020-7489(18)30013-0 10.1016/j.ijnurstu.2018.01.003 Diabetes Mellitus type 1 (T1DM) is a chronic disease that requires patients' self-monitoring and self-management to achieve glucose targets and prevent (...) of Endocrinology and Metabolism, 1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece. Electronic address: kkalli@auth.gr. eng Journal Article 2018 01 06 England Int J Nurs Stud 0400675 0020-7489 Diabetes management Diabetes type 1 Monitoring Nursing care Telenursing 2017 04 19 2017 12 27 2018 01 05 2018 1 23 6 0 2018 1 23 6 0 2018 1 23 6 0 aheadofprint 29353709 S0020-7489(18)30013-0 10.1016/j.ijnurstu.2018.01.003

EvidenceUpdates2018

158. Bariatric surgery for Type 2 Diabetes and a body mass index below 35

, 44% of patients in the surgery group achieved remission of type 2 diabetes compared to 3% in the control group. We have moderate confidence in the effect estimate. On average, HbA1c concentrations were reduced by 1 to 1.5 percentage points more than standard treatment. We have moderate confidence in the effect estimate. Fasting glucose concentrations were reduced. We have moderate confidence in the effect estimate. Health-related quality of life was only investigated in one study. BMI was on (...) Bariatric surgery for Type 2 Diabetes and a body mass index below 35 Bariatric surgery for Type 2 Diabetes and a body mass index below 35 - Health Technology Assessment - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • Bariatric surgery for Type 2 Diabetes and a body mass index below 35 - Health Technology Assessment Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment

Norwegian Institute of Public Health2018